top of page

Mwandishi

Mhariri:

ULY CLINIC

Dkt. Benjamin L, MD

16 Machi 2021, 16:00:18

Esomeprazole na ujauzito

Esomeprazole na ujauzito

Esomeprazole nidawa jamii ya Proton pump inhibitor (PPI).Kuna taarifa chache sana kuhusu matumizi ya dawa hii kwenye ujauzito, hata hivyo kuna tafiti moja inaonyesha kuwepo kwa uhusiano kati ya pumu ya kifua na aleji kwa watoto wanaozaliwa na mama aliyetumia dawa hii wakati wa ujauzito, hata hivyo tafiti hii inatakiwa kuthibitishwa.


Taarifa kutoka kwa wanyama na binadamu wajawazito zinaonyesha kuwepo kwa hatari kidogo ya madhaifu ya kiuumbaji kwa watumiaji wa dawa zingine jamii ya PPI, hata hivyo hatari ya matumizi ya esomeprazole haiwezi kuchunguzwa kiundani bila kuwa na taarifa zingine kutoka kwa watumiaji wa dawa hii kwenye ujauzito. Mpaka taarifa hizo zipatikane, kwa sasa ni vema kutumia dawa zingine jamii ya PPI endapo itahitajika wakati wa ujauzito kamalansoprazole au pantoprazole.


Ushauri dhidi ya matumizi kwa mama mjamzito


Hakuna (zipo chache) taarifa za binadamu- taarifa za wanyama zinaonyesha kuwepo hatari kidogo


Hakuna (zipo chache) taarifa za binadamu- taarifa za wanyama zinaonyesha kuwepo hatari kidogo ina maanisha nini?

Inawezekana kuwa hakuna taarifa za zoefu wa matumizi ya dawa hii au taarifa za binadamu wajawazito wachache waliotumia dawa hii zimeonyesha kutohusiana kuwa sumu kwa kichangawa tumboni kuweza kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo endapo itatumika. Dawa haileti sumu kwenye uumbaji wa kijusi (kwenye dozi ambayo haikusababisha sumu kwa mama) kwenye jamii zote za wanyama waliofanyiwa tafiti kwenye dozi ambayo ni sawa au pungufu ya mara kumi ya ile ya binadamu, dozi inayotolewa kuendana na jumla ya eneo la mwili


Ushauri wa matumizi kwa mama anayenyonyesha


Hakuna (chache) taarifa kwa binadamu- inaweza kuwa sumu kwenye ukuaji wa kichanga


Hakuna (chache) taarifa kwa binadamu- inaweza kuwa sumu kwenye ukuaji wa kichanga ina maanisha nini?

Inaweza kuwa taarifa juu ya matumizi kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii hazipo au zipo chache. Sifa za ufanyaji kazi wa dawa zinaonyesha kuwa dawa hii inaweza kuwa sumu kwa kichanga anayenyonya. Hairuhusiwi kumnyonyesha mtoto unapotumia dawa hii.

ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

4 Juni 2025, 19:23:48

​

  1. Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in Pregnancy and Risk of Major Congenital Malformations and Fetal Death. JAMA. 2013;310(15):1601–11. doi:10.1001/jama.2013.278343

  2. Sun L, Xi Y, et al. Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. PLoS One. [Internet]. 2022 [cited 2022 Apr 20]. Available from: https://doi.org/10.1371/journal.pone.0257584

  3. Bérard A, et al. New evidence for concern over the risk of birth defects from medications for nausea and vomiting of pregnancy. J Clin Epidemiol. 2019 [cited 2022 Apr 20]. Available from: https://doi.org/10.1016/j.jclinepi.2019.07.014

  4. Bylsma-Howell M, et al. Placental transport of metoclopramide: assessment of maternal and neonatal effects. Can Anaesth Soc J. 1983;30:487–92.

  5. Arvela P, et al. Placental transfer and hormonal effects of metoclopramide. Eur J Clin Pharmacol. 1983;24:345–8.

  6. Cohen SE, et al. Does metoclopramide decrease the volume of gastric contents in patients undergoing cesarean section? Anesthesiology. 1984;61:604–7.

  7. Lyonnet R, Lucchini G. Metoclopramide in obstetrics. J Med Chir Prat. 1967;138:352–5.

  8. Sidhu MS, Lean TH. The use of metoclopramide (Maxolon) in hyperemesis gravidarum. Proc Obstet Gynaecol Soc Singapore. 1970;1:1–4.

  9. Guikontes E, Spantideas A, Diakakis J. Ondansetron and hyperemesis gravidarum. Lancet. 1992;340:1223.

  10. Martynshin MYA, et al. Experience in treating early toxicoses of pregnancy with metoclopramide. Akush Ginekol. 1981;57:44–5.

  11. Pinder RM, et al. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs. 1976;12:81–131.

  12. Harrington RA, et al. Metoclopramide: an update review of its pharmacological properties and clinical use. Drugs. 1983;25:451–94.

  13. McGarry JM. A double-blind comparison of the anti-emetic effect during labour of metoclopramide and perphenazine. Br J Anaesth. 1971;43:613–5.

  14. Howard FA, Sharp DS. Effect of metoclopramide on gastric emptying during labour. Br Med J. 1973;1:446–8.

  15. Brock-Utne JG, et al. The effect of metoclopramide on the lower oesophageal sphincter in late pregnancy. Anaesth Intensive Care. 1978;6:26–9.

  16. Hey VMF, Ostick DG. Metoclopramide and the gastro-oesophageal sphincter. Anaesthesia. 1978;33:462–5.

  17. Feeney JG. Heartburn in pregnancy. Br Med J. 1982;284:1138–9.

  18. Murphy DF, et al. Effect of metoclopramide on gastric emptying before elective and emergency caesarean section. Br J Anaesth. 1984;56:1113–6.

  19. Vella L, Francis D, Houlton P, Reynolds F. Comparison of the antiemetics metoclopramide and promethazine in labour. Br Med J. 1985;290:1173–5.

  20. Messinis IE, et al. Effect of metoclopramide on maternal and fetal prolactin secretion during labor. Obstet Gynecol. 1982;60:686–8.

  21. Bohnet HG, Kato K. Prolactin secretion during pregnancy and puerperium: response to metoclopramide and interactions with placental hormones. Obstet Gynecol. 1985;65:789–92.

  22. Roti E, et al. Failure of metoclopramide to affect thyrotropin concentration in the term human fetus. J Clin Endocrinol Metab. 1983;56:1071–5.

  23. Milo R, et al. Acute intermittent porphyria in pregnancy. Obstet Gynecol. 1989;73:450–2.

  24. Nageotte MP, et al. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am J Obstet Gynecol. 1996;174:1801–6.

  25. Turcotte V, et al. Utilité du dropéridol et de la diphenhydramine dans l’hyperemesis gravidarum. J Soc Obstet Gynaecol Can. 2001;23:133–9.

  26. Sorensen HT, et al. Birth outcome following maternal use of metoclopramide. Br J Clin Pharmacol. 2000;49:264–8.

  27. Berkovitch M, et al. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. N Engl J Med. 2000;343:445–6.

  28. Product information. Reglan. A.H. Robins; 1997.

  29. Eisenach JC, Dewan DM. Metoclopramide exaggerates stress-induced tachycardia in pregnant sheep. Anesth Analg. 1996;82:607–11.

  30. Shenhav S, et al. Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. Acta Obstet Gynecol Scand. 1997;76:484–5.

  31. Orr DA, et al. Effects of omeprazole, with and without metoclopramide, in elective obstetric anaesthesia. Anaesthesia. 1993;48:114–9.

  32. Stuart JC, et al. Acid aspiration prophylaxis for emergency caesarean section. Anaesthesia. 1996;51:415–21.

  33. Robuschi G, et al. Failure of metoclopramide to release GH in pregnant women. Horm Metab Res. 1983;15:460–1.

  34. Lewis PJ, Devenish C, Kahn C. Controlled trial of metoclopramide in the initiation of breast feeding. Br J Clin Pharmacol. 1980;9:217, 219.

  35. Pelkonen O, et al. Metoclopramide in breast milk and newborn (abstract). Acta Physiol Scand. 1982;(Suppl 502):62.

  36. Kauppila A, et al. Metoclopramide and breast feeding: transfer into milk and the newborn. Eur J Clin Pharmacol. 1983;25:819–23.

  37. Sousa PLR. Metoclopramide and breast-feeding. Br Med J. 1975;1:512.

  38. Guzman V, et al. Improvement of defective lactation by using oral metoclopramide. Acta Obstet Gynecol Scand. 1979;58:53–5.

  39. Kauppila A, et al. Metoclopramide increases prolactin release and milk secretion in puerperium without stimulating the secretion of thyrotropin and thyroid hormones. J Clin Endocrinol Metab. 1981;52:436–9.

  40. Kauppila A, et al. A dose response relation between improved lactation and metoclopramide. Lancet. 1981;1:1175–7.

  41. de Gezelle H, et al. Metoclopramide and breast milk. Eur J Obstet Gynecol Reprod Biol. 1983;15:31–6.

  42. Kauppila A, et al. Metoclopramide and breast feeding: efficacy and anterior pituitary responses of the mother and the child. Eur J Obstet Gynecol Reprod Biol. 1985;19:19–22.

  43. Gupta AP, Gupta PK. Metoclopramide as a lactogogue. Clin Pediatr. 1985;24:269–72.

  44. Ehrenkranz RA, Ackerman BA. Metoclopramide effect on faltering milk production by mothers of premature infants. Pediatrics. 1986;78:614–20.

  45. Budd SC, et al. Improved lactation with metoclopramide. Clin Pediatr. 1993;32:53–7.

  46. Toppare MF, et al. Metoclopramide for breast milk production. Nutrition Research. 1994;14:1019–29.

  47. Sankaran K, et al. Use of metoclopramide in preterm infants. Dev Pharmacol Ther. 1982;5:114–9.

  48. Lewis JH, Weingold AB, Committee on FDA-Related Matters, American College of Gastroenterology. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol. 1985;80:912–23.

  49. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics. 200

bottom of page